VA/DoD Formulary To Pick Triptan In May; GSK Imitrex Protest Denied
Executive Summary
The Departments of Defense and Veterans Affairs expect to make a formulary decision on the triptan class of migraine products in May
You may also be interested in...
AstraZeneca Zomig on VA/DoD formulary
AstraZeneca's Zomig (zolmitriptan) will be sole triptan on formulary of the Departments of Defense and Veteran Affairs effective July 11. AstraZeneca won the contract by offering a price of $3.20 per tablet, 57% less than Zomig's cheapest price on the Federal Supply Schedule ($44.21 for a six tablet pack of Zomig-ZMT 2.5 mg). The departments had also been considering Pharmacia's - now Ortho-McNeil's - Axert (almotriptan), GlaxoSmithKline's Imitrex (sumatriptan) and Merck's Maxalt (rizatriptan) (1"The Pink Sheet" April 14, 2003, p. 25)...
AstraZeneca Zomig on VA/DoD formulary
AstraZeneca's Zomig (zolmitriptan) will be sole triptan on formulary of the Departments of Defense and Veteran Affairs effective July 11. AstraZeneca won the contract by offering a price of $3.20 per tablet, 57% less than Zomig's cheapest price on the Federal Supply Schedule ($44.21 for a six tablet pack of Zomig-ZMT 2.5 mg). The departments had also been considering Pharmacia's - now Ortho-McNeil's - Axert (almotriptan), GlaxoSmithKline's Imitrex (sumatriptan) and Merck's Maxalt (rizatriptan) (1"The Pink Sheet" April 14, 2003, p. 25)...
Pfizer Relpax To Launch In First Quarter At Maximum Dose Of 40 Mg
Pfizer's Relpax migraine treatment will be launched during the first quarter at a maximum dose of 40 mg